Protagonist Therapeutics, Inc
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $46.0M | $434.4M | $60.0M | $26.6M | $27.4M |
| Operating income | -$158.1M | $252.8M | -$93.7M | -$131.4M | -$125.8M |
| Operating expenses | $204.1M | $181.6M | $153.7M | $158.0M | $153.2M |
| Cash from operations | $57.7M | $184.2M | -$70.2M | -$108.1M | -$107.9M |
| Capital expenditure | $1.6M | $1.4M | $609,000 | $795,000 | $1.1M |
| Free cash flow | $56.1M | $182.8M | -$70.8M | -$108.9M | -$109.0M |
| Total assets | $668.2M | $744.7M | $358.0M | $247.9M | $347.7M |
| Total liabilities | $53.5M | $69.4M | $21.3M | $32.3M | $47.7M |
Shares outstanding 64.3M · Free float 94.6%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.